UNSPSC 51363004: Clomethiazole edisylate

This classification denotes a sedative and hypnotic with the molecular formula 2C6H8ClNS.C2H6O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 22NJI0W1D2, chemically known as 5-(2-chloroethyl)-4-methylthiazole ethane-1,2-disulphonate, but more generally known as clomethiazole edisylate, which bears US NIH Compound Identifier 15850. European Medicines Agency schedules clomethiazole edisylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06720MIG.

Most nations, for tariff purposes, schedule clomethiazole edisylate under HS 29341000. SMILES: CC1C(SCN1)CCCL.CC1C(SCN1)CCCL.C(CS(=O)(=O)O)S(=O)(=O)O.

UNSPSC 51363004 Clomethiazole edisylate is a Commodity code that nominally covers a single pharmaceutical active ingredient, but recent state and local solicitations tagged under this code reflect much broader pharmaceutical procurement — including naloxone distribution, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. The mismatch between the code name and the actual work being solicited suggests that state and local procurement offices are using this code as a catch-all for pharmaceutical supply and pharmacy benefit initiatives rather than for clomethiazole specifically. State and local issuing bodies active under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple states (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, which includes Oregon).

Recent activity spans Florida, Texas, and the MMCAP multi-state region. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with responses due July 26, 2023. Texas HHS issued RFI HHS0017013 on April 3, 2026, gathering vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, signaling the state's intent to explore direct contracting models outside traditional pharmacy benefit manager arrangements. MMCAP released RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities, with proposals due March 26, 2026, and awarded vendor lists to be provided to authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) by May 15, 2026. The MMCAP procurement emphasizes price competitiveness (75 percent weight), compliance with cGMP and DSCSA requirements, and flexible net-pricing models; Seminole County requires E-Verify and drug-free workplace certification with a two-year initial term and one-year renewal option.